Biotech · Public company · San Diego, CA, US
aTYR PHARMA INC
Ticker ATYR · SEC CIK 0001339970
Track this companyFree. Adds aTYR PHARMA INC to your Dealase workspace and tells you when its record changes.
Clinical trials91 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline9
- Efzofitimod 3 mg/kgPhase 3 · Pulmonary SarcoidosisClinicalTrials.gov · fetched Nov 12, 2026
- Efzofitimod 5 mg/kgPhase 3 · Pulmonary SarcoidosisClinicalTrials.gov · fetched Nov 12, 2026
- ATYR1940Phase 2 · Limb-Girdle Muscular DystrophiesClinicalTrials.gov · fetched Nov 12, 2026
- ATYR1940Phase 2 · Facioscapulohumeral Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
- ATYR1940Phase 2 · Facioscapulohumeral Muscular Dystrophy (FSHD)ClinicalTrials.gov · fetched Nov 12, 2026
- Efzofitimod 1 mg/kgPhase 2 · SARS-CoV-2 (COVID-19) Severe PneumoniaClinicalTrials.gov · fetched Nov 12, 2026
- efzofitimod 270 mgPhase 2 · Interstitial Lung DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Efzofitimod 3 mg/kgPhase 2 · SARS-CoV-2 (COVID-19) Severe PneumoniaClinicalTrials.gov · fetched Nov 12, 2026
- efzofitimod 450 mgPhase 2 · Interstitial Lung DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials9
- Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)PHASE2 · RECRUITING · started Oct 26, 2023ClinicalTrials.gov NCT05892614 · fetched Nov 12, 2026
- Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary SarcoidosisPHASE3 · COMPLETED · started Sep 15, 2022ClinicalTrials.gov NCT05415137 · fetched Nov 12, 2026
- Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19PHASE2 · COMPLETED · started Jun 4, 2020ClinicalTrials.gov NCT04412668 · fetched Nov 12, 2026
- Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary SarcoidosisPHASE1_PHASE2 · COMPLETED · started Jan 29, 2019ClinicalTrials.gov NCT03824392 · fetched Nov 12, 2026
- Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD)PHASE1_PHASE2 · COMPLETED · started Jul 13, 2016ClinicalTrials.gov NCT02836418 · fetched Nov 12, 2026
- Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular DystrophyPHASE1_PHASE2 · COMPLETED · started Mar 30, 2016ClinicalTrials.gov NCT02603562 · fetched Nov 12, 2026
- Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD)PHASE1_PHASE2 · COMPLETED · started Nov 30, 2015ClinicalTrials.gov NCT02579239 · fetched Nov 12, 2026
- Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy - Study ExtensionPHASE1_PHASE2 · COMPLETED · started Aug 13, 2015ClinicalTrials.gov NCT02531217 · fetched Nov 12, 2026
- Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular DystrophyPHASE1_PHASE2 · COMPLETED · started Sep 4, 2014ClinicalTrials.gov NCT02239224 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Nov 6, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 27, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 16, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 24, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 7, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 7, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 31, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 8, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 1, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 15, 2026 · fetched Nov 12, 2026